See What HealthDay Can Do For You
Contact Us

Hidradenitis Suppurativa Tied to Adverse Cardiovascular Outcomes

After adjustment for confounding variables, higher risk of adverse CV outcomes, all-cause mortality

chest exam

WEDNESDAY, Feb. 17, 2016 (HealthDay News) -- Hidradenitis suppurativa (HS) is independently associated with increased risk of adverse cardiovascular (CV) outcomes, according to a study published online Feb. 17 in JAMA Dermatology.

Alexander Egeberg, M.D., Ph.D., from the University of Copenhagen in Denmark, and colleagues conducted a population-based study to examine CV risk in patients with HS. Data were included for 5,964 patients aged 18 years or older with a hospital-based diagnosis of HS (cases) matched on age, sex, and calendar year with 29,404 controls.

The researchers found that the incidence rate ratios were 1.57 for myocardial infarction, 1.33 for ischemic stroke, 1.95 for CV-associated death, 1.53 for major adverse cardiovascular events (MACEs), and 1.35 for all-cause mortality, after adjustment for age, sex, socioeconomic status, smoking, comorbidity, and medication. Compared to patients with severe psoriasis, the adjusted incidence rates ratios were only significant for CV-associated death (adjusted incidence rate ratio, 1.58), but not for myocardial infarction, ischemic stroke, MACEs, and all-cause mortality.

"Hidradenitis suppurativa was associated with a significantly increased risk of adverse CV outcomes and all-cause mortality independent of measured confounders," the authors write. "The results call for increased awareness of this association and for studies of its clinical consequences."

Abstract
Full Text (subscription or payment may be required)

Physician's Briefing

HealthDay

HealthDay is the world’s largest syndicator of health news and content, and providers of custom health/medical content.

Consumer Health News

A health news feed, reviewing the latest and most topical health stories.

Professional News

A news feed for Health Care Professionals (HCPs), reviewing latest medical research and approvals.